In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manufacturing Round-Up: Dr Reddy’s Receives Form 483 With Five Observations

Executive Summary

As firms including Laurus Labs, Natco and Strides get GMP compliance nods, the FDA has pulled up Dr Reddy’s for GMP compliance issues. Meanwhile, Numaferm has struck a licensing deal and Olon has started constructing a new plant.

You may also be interested in...



Bortezomib Boom Benefits Stada But Pemetrexed Position Proves Perplexing

Launching the oncology drug bortezomib in 14 European countries helped Stada to record an 11% increase in both Generics and group sales in the first half of 2019. But the German group, which is about to start rolling out biosimilar teriparatide, has suffered a legal setback on pemetrexed in its home market.

US FDA Warning Letter Hits Strides On Data Integrity

Even after the US FDA warns Strides on uncontrolled records destruction and poor OOS investigations at its Puducherry plant, firm remains confident in its US market growth projections.

Reddy’s Gets Six-Month Head Start On Carboprost In US

Dr Reddy’s will be alone in the US market for six months with the first generic rival to Pfizer’s Hemabate carboprost brand.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel